

Special Issue

Recent Advances in Molecular Cancer Therapeutics

Message from the Guest Editor

The Special Issue "Recent Advances in Molecular Cancer Therapeutics" focuses on recent advances in molecular cancer therapeutics, especially new anticancer drug discovery and development. The article may be either a full paper or a communication based on your research in molecular cancer therapeutics or may be a focused review article on some aspect of the subject. Potential topics can include but are not limited to the following research areas:

- Anticancer drug discovery and development
- Cancer metabolism
- Cancer inflammatory microenvironment
- Cancer biomarkers
- Cancer therapy
- The discovery and preclinical development of novel therapeutic agents for oncology
- Preclinical studies of approved therapeutics
- Mechanisms of drug action
- Mechanisms of drug resistance
- Biomarkers of drug response
- Novel models and technologies
- Occasional drug toxicity mechanisms


Guest Editor

Dr. Alok Ranjan

Department of Biomedical Science, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA

Deadline for manuscript submissions

closed (30 September 2021)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



mdpi.com/si/79286

Molecules
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.6
CiteScore 8.6
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the first half of 2025).